A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non–Small Cell Lung Cancer

Published:2012-06 Issue:6 Volume:7 Page:963-972
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Cuffe Sinead,Bourredjem Abderrahmane,Graziano Stephen,Pignon Jean-Pierre,Domerg Caroline,Ezzalfani Monia,Seymour Lesley,Strevel Elizabeth,Burkes Ronald,Capelletti Marzia,Jänne Pasi A,Tsao Ming-Sound,Shepherd Frances A.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data;Lancet,2010

2. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer;Arriagada;N Engl J Med,2004

3. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial;Douillard;Lancet Oncol,2006

4. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer;Winton;N Engl J Med,2005

5. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J Clin Oncol,2008

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer;Cancer Medicine;2023-09-15

2. Prediction of disease-free survival of N1/2 non-small cell lung cancer after adjuvant chemotherapy by the biomarker RPMB;Heliyon;2023-07

3. Adjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules;The Annals of Thoracic Surgery;2022-02

4. High RPMB Predicts Better Disease-Free Survival of N1/2 Non-Small Cell Lung Cancer after Adjuvant Chemotherapy;SSRN Electronic Journal;2022

5. Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition;Cancers;2021-04-10